nodes	percent_of_prediction	percent_of_DWPC	metapath
Methamphetamine—L-Phenylalanine—Liothyronine—hypothyroidism	0.629	1	CrCrCtD
Methamphetamine—Cardio-respiratory arrest—Liothyronine—hypothyroidism	0.0497	0.351	CcSEcCtD
Methamphetamine—Cardio-respiratory arrest—Liotrix—hypothyroidism	0.018	0.127	CcSEcCtD
Methamphetamine—Tachycardia—Liothyronine—hypothyroidism	0.00618	0.0437	CcSEcCtD
Methamphetamine—SLC18A1—adrenal gland—hypothyroidism	0.00526	0.0504	CbGeAlD
Methamphetamine—TAAR1—thyroid gland—hypothyroidism	0.00477	0.0457	CbGeAlD
Methamphetamine—SLC6A3—nerve—hypothyroidism	0.00459	0.044	CbGeAlD
Methamphetamine—SLC22A3—tongue—hypothyroidism	0.00422	0.0404	CbGeAlD
Methamphetamine—MAOB—nerve—hypothyroidism	0.00399	0.0383	CbGeAlD
Methamphetamine—SLC6A2—nerve—hypothyroidism	0.0037	0.0355	CbGeAlD
Methamphetamine—Tremor—Dextrothyroxine—hypothyroidism	0.00357	0.0252	CcSEcCtD
Methamphetamine—Tremor—Levothyroxine—hypothyroidism	0.00357	0.0252	CcSEcCtD
Methamphetamine—Agitation—Dextrothyroxine—hypothyroidism	0.0035	0.0248	CcSEcCtD
Methamphetamine—Agitation—Levothyroxine—hypothyroidism	0.0035	0.0248	CcSEcCtD
Methamphetamine—MAOA—nerve—hypothyroidism	0.00341	0.0327	CbGeAlD
Methamphetamine—Palpitations—Levothyroxine—hypothyroidism	0.00337	0.0238	CcSEcCtD
Methamphetamine—Palpitations—Dextrothyroxine—hypothyroidism	0.00337	0.0238	CcSEcCtD
Methamphetamine—Tachycardia—Levothyroxine—hypothyroidism	0.00304	0.0215	CcSEcCtD
Methamphetamine—Tachycardia—Dextrothyroxine—hypothyroidism	0.00304	0.0215	CcSEcCtD
Methamphetamine—CYP2D6—urine—hypothyroidism	0.00294	0.0281	CbGeAlD
Methamphetamine—Insomnia—Levothyroxine—hypothyroidism	0.00281	0.0199	CcSEcCtD
Methamphetamine—Insomnia—Dextrothyroxine—hypothyroidism	0.00281	0.0199	CcSEcCtD
Methamphetamine—Tremor—Liotrix—hypothyroidism	0.00263	0.0186	CcSEcCtD
Methamphetamine—Agitation—Liotrix—hypothyroidism	0.00258	0.0182	CcSEcCtD
Methamphetamine—Palpitations—Liotrix—hypothyroidism	0.00248	0.0175	CcSEcCtD
Methamphetamine—Urticaria—Levothyroxine—hypothyroidism	0.00247	0.0175	CcSEcCtD
Methamphetamine—Urticaria—Dextrothyroxine—hypothyroidism	0.00247	0.0175	CcSEcCtD
Methamphetamine—Tachycardia—Liotrix—hypothyroidism	0.00223	0.0158	CcSEcCtD
Methamphetamine—Diarrhoea—Dextrothyroxine—hypothyroidism	0.00213	0.015	CcSEcCtD
Methamphetamine—Diarrhoea—Levothyroxine—hypothyroidism	0.00213	0.015	CcSEcCtD
Methamphetamine—Insomnia—Liotrix—hypothyroidism	0.00207	0.0146	CcSEcCtD
Methamphetamine—Constipation—Liotrix—hypothyroidism	0.00196	0.0138	CcSEcCtD
Methamphetamine—Headache—Dextrothyroxine—hypothyroidism	0.00195	0.0138	CcSEcCtD
Methamphetamine—Headache—Levothyroxine—hypothyroidism	0.00195	0.0138	CcSEcCtD
Methamphetamine—Urticaria—Liotrix—hypothyroidism	0.00182	0.0128	CcSEcCtD
Methamphetamine—Hypersensitivity—Liotrix—hypothyroidism	0.00169	0.0119	CcSEcCtD
Methamphetamine—SLC18A2—adrenal gland—hypothyroidism	0.00168	0.0161	CbGeAlD
Methamphetamine—SLC18A2—blood—hypothyroidism	0.00168	0.0161	CbGeAlD
Methamphetamine—SLC18A2—thyroid gland—hypothyroidism	0.00162	0.0155	CbGeAlD
Methamphetamine—Diarrhoea—Liotrix—hypothyroidism	0.00157	0.0111	CcSEcCtD
Methamphetamine—MAOB—adrenal cortex—hypothyroidism	0.00153	0.0147	CbGeAlD
Methamphetamine—Dizziness—Liotrix—hypothyroidism	0.00151	0.0107	CcSEcCtD
Methamphetamine—MAOB—heart—hypothyroidism	0.00148	0.0142	CbGeAlD
Methamphetamine—Headache—Liotrix—hypothyroidism	0.00143	0.0101	CcSEcCtD
Methamphetamine—MAOB—cardiovascular system—hypothyroidism	0.0014	0.0134	CbGeAlD
Methamphetamine—SLC18A2—testis—hypothyroidism	0.00139	0.0133	CbGeAlD
Methamphetamine—SLC22A3—gonad—hypothyroidism	0.00137	0.0132	CbGeAlD
Methamphetamine—SLC18A2—liver—hypothyroidism	0.00131	0.0126	CbGeAlD
Methamphetamine—MAOA—adrenal cortex—hypothyroidism	0.00131	0.0125	CbGeAlD
Methamphetamine—SLC18A2—cerebellum—hypothyroidism	0.00128	0.0123	CbGeAlD
Methamphetamine—MAOA—heart—hypothyroidism	0.00127	0.0121	CbGeAlD
Methamphetamine—ADRA2C—adrenal cortex—hypothyroidism	0.00126	0.0121	CbGeAlD
Methamphetamine—MAOB—pituitary gland—hypothyroidism	0.00124	0.0119	CbGeAlD
Methamphetamine—ADRA2C—heart—hypothyroidism	0.00122	0.0117	CbGeAlD
Methamphetamine—SLC22A5—adrenal cortex—hypothyroidism	0.00121	0.0116	CbGeAlD
Methamphetamine—SLC22A3—adrenal gland—hypothyroidism	0.0012	0.0115	CbGeAlD
Methamphetamine—MAOA—cardiovascular system—hypothyroidism	0.00119	0.0114	CbGeAlD
Methamphetamine—SLC6A2—gonad—hypothyroidism	0.00118	0.0113	CbGeAlD
Methamphetamine—SLC22A5—heart—hypothyroidism	0.00117	0.0112	CbGeAlD
Methamphetamine—SLC6A4—blood—hypothyroidism	0.00116	0.0112	CbGeAlD
Methamphetamine—SLC22A3—thyroid gland—hypothyroidism	0.00115	0.0111	CbGeAlD
Methamphetamine—SLC22A3—female gonad—hypothyroidism	0.00112	0.0107	CbGeAlD
Methamphetamine—MAOB—adrenal gland—hypothyroidism	0.00111	0.0106	CbGeAlD
Methamphetamine—MAOB—blood—hypothyroidism	0.00111	0.0106	CbGeAlD
Methamphetamine—MAOB—thyroid gland—hypothyroidism	0.00107	0.0102	CbGeAlD
Methamphetamine—MAOA—pituitary gland—hypothyroidism	0.00106	0.0101	CbGeAlD
Methamphetamine—SLC6A3—testis—hypothyroidism	0.00105	0.0101	CbGeAlD
Methamphetamine—MAOB—female gonad—hypothyroidism	0.00103	0.0099	CbGeAlD
Methamphetamine—SLC6A2—adrenal gland—hypothyroidism	0.00103	0.00983	CbGeAlD
Methamphetamine—ADRA2C—pituitary gland—hypothyroidism	0.00102	0.00975	CbGeAlD
Methamphetamine—SLC22A3—testis—hypothyroidism	0.000989	0.00949	CbGeAlD
Methamphetamine—SLC22A5—pituitary gland—hypothyroidism	0.000974	0.00934	CbGeAlD
Methamphetamine—ADRA2A—heart—hypothyroidism	0.000971	0.00931	CbGeAlD
Methamphetamine—SLC6A3—cerebellum—hypothyroidism	0.00097	0.00931	CbGeAlD
Methamphetamine—MAOA—adrenal gland—hypothyroidism	0.000944	0.00906	CbGeAlD
Methamphetamine—MAOA—blood—hypothyroidism	0.000944	0.00905	CbGeAlD
Methamphetamine—SLC22A3—liver—hypothyroidism	0.000935	0.00897	CbGeAlD
Methamphetamine—MAOB—testis—hypothyroidism	0.000915	0.00878	CbGeAlD
Methamphetamine—MAOA—thyroid gland—hypothyroidism	0.000911	0.00874	CbGeAlD
Methamphetamine—ADRA2C—adrenal gland—hypothyroidism	0.000908	0.00871	CbGeAlD
Methamphetamine—ADRA2C—blood—hypothyroidism	0.000908	0.00871	CbGeAlD
Methamphetamine—MAOA—female gonad—hypothyroidism	0.000881	0.00844	CbGeAlD
Methamphetamine—SLC22A5—adrenal gland—hypothyroidism	0.00087	0.00834	CbGeAlD
Methamphetamine—SLC22A5—blood—hypothyroidism	0.00087	0.00834	CbGeAlD
Methamphetamine—MAOB—liver—hypothyroidism	0.000866	0.0083	CbGeAlD
Methamphetamine—SLC6A2—testis—hypothyroidism	0.000848	0.00813	CbGeAlD
Methamphetamine—ADRA2C—female gonad—hypothyroidism	0.000847	0.00812	CbGeAlD
Methamphetamine—MAOB—cerebellum—hypothyroidism	0.000846	0.00811	CbGeAlD
Methamphetamine—SLC22A5—thyroid gland—hypothyroidism	0.000839	0.00805	CbGeAlD
Methamphetamine—ADRA2A—gonad—hypothyroidism	0.000831	0.00797	CbGeAlD
Methamphetamine—ADRA2A—pituitary gland—hypothyroidism	0.000811	0.00778	CbGeAlD
Methamphetamine—SLC22A5—female gonad—hypothyroidism	0.000811	0.00778	CbGeAlD
Methamphetamine—MAOA—testis—hypothyroidism	0.000781	0.00749	CbGeAlD
Methamphetamine—ADRA2C—testis—hypothyroidism	0.000751	0.0072	CbGeAlD
Methamphetamine—MAOA—liver—hypothyroidism	0.000738	0.00708	CbGeAlD
Methamphetamine—ADRA2A—adrenal gland—hypothyroidism	0.000725	0.00695	CbGeAlD
Methamphetamine—ADRA2A—blood—hypothyroidism	0.000724	0.00695	CbGeAlD
Methamphetamine—MAOA—cerebellum—hypothyroidism	0.000721	0.00692	CbGeAlD
Methamphetamine—SLC22A5—testis—hypothyroidism	0.000719	0.0069	CbGeAlD
Methamphetamine—ADRA2C—liver—hypothyroidism	0.00071	0.00681	CbGeAlD
Methamphetamine—ADRA2A—thyroid gland—hypothyroidism	0.000699	0.0067	CbGeAlD
Methamphetamine—ADRA2C—cerebellum—hypothyroidism	0.000694	0.00665	CbGeAlD
Methamphetamine—SLC22A5—liver—hypothyroidism	0.00068	0.00652	CbGeAlD
Methamphetamine—ADRA2A—female gonad—hypothyroidism	0.000676	0.00648	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—TRH—hypothyroidism	0.000667	0.00534	CbGpPWpGaD
Methamphetamine—SLC22A5—cerebellum—hypothyroidism	0.000664	0.00637	CbGeAlD
Methamphetamine—SLC6A4—Circadian rythm related genes—NKX2-1—hypothyroidism	0.000659	0.00527	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000657	0.00526	CbGpPWpGaD
Methamphetamine—MAOA—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000654	0.00523	CbGpPWpGaD
Methamphetamine—TAAR1—G alpha (s) signalling events—POMC—hypothyroidism	0.000642	0.00513	CbGpPWpGaD
Methamphetamine—SLC18A1—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000637	0.0051	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—THRB—hypothyroidism	0.000631	0.00505	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmission across Chemical Synapses—SLC5A7—hypothyroidism	0.000608	0.00486	CbGpPWpGaD
Methamphetamine—ADRA2A—testis—hypothyroidism	0.000599	0.00575	CbGeAlD
Methamphetamine—TAAR1—GPCR ligand binding—TSHB—hypothyroidism	0.000595	0.00476	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—TSHR—hypothyroidism	0.000595	0.00476	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000592	0.00474	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000591	0.00472	CbGpPWpGaD
Methamphetamine—CYP2D6—blood—hypothyroidism	0.000561	0.00538	CbGeAlD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000556	0.00445	CbGpPWpGaD
Methamphetamine—ADRA2A—cerebellum—hypothyroidism	0.000553	0.00531	CbGeAlD
Methamphetamine—CYP2D6—female gonad—hypothyroidism	0.000523	0.00502	CbGeAlD
Methamphetamine—SLC18A2—Neuronal System—NEFL—hypothyroidism	0.000504	0.00403	CbGpPWpGaD
Methamphetamine—MAOA—Neuronal System—SLC5A7—hypothyroidism	0.000501	0.00401	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A7—hypothyroidism	0.000493	0.00394	CbGpPWpGaD
Methamphetamine—SLC6A3—Neuronal System—SLC5A7—hypothyroidism	0.000466	0.00373	CbGpPWpGaD
Methamphetamine—CYP2D6—testis—hypothyroidism	0.000464	0.00445	CbGeAlD
Methamphetamine—MAOB—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000463	0.0037	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000461	0.00369	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.00046	0.00368	CbGpPWpGaD
Methamphetamine—CYP2D6—liver—hypothyroidism	0.000439	0.00421	CbGeAlD
Methamphetamine—CYP2D6—cerebellum—hypothyroidism	0.000429	0.00411	CbGeAlD
Methamphetamine—MAOA—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000421	0.00337	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.00042	0.00336	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000411	0.00329	CbGpPWpGaD
Methamphetamine—SLC6A4—NRF2 pathway—SLC5A5—hypothyroidism	0.00041	0.00328	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC26A4—hypothyroidism	0.000408	0.00327	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmission across Chemical Synapses—NEFL—hypothyroidism	0.000392	0.00313	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TRH—hypothyroidism	0.000377	0.00302	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000363	0.00291	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000362	0.0029	CbGpPWpGaD
Methamphetamine—SLC6A2—NRF2 pathway—SLC5A5—hypothyroidism	0.000353	0.00282	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—AVP—hypothyroidism	0.000351	0.00281	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000348	0.00279	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TRH—hypothyroidism	0.000342	0.00274	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TSHB—hypothyroidism	0.000336	0.00269	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—TSHR—hypothyroidism	0.000336	0.00269	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.00033	0.00264	CbGpPWpGaD
Methamphetamine—SLC18A1—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000324	0.00259	CbGpPWpGaD
Methamphetamine—MAOA—Neuronal System—NEFL—hypothyroidism	0.000323	0.00258	CbGpPWpGaD
Methamphetamine—SLC6A3—NRF2 pathway—SLC5A5—hypothyroidism	0.000313	0.0025	CbGpPWpGaD
Methamphetamine—SLC6A4—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000306	0.00245	CbGpPWpGaD
Methamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	0.000306	0.00245	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TSHB—hypothyroidism	0.000305	0.00244	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—TSHR—hypothyroidism	0.000305	0.00244	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000301	0.00241	CbGpPWpGaD
Methamphetamine—SLC6A3—Neuronal System—NEFL—hypothyroidism	0.0003	0.0024	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.0003	0.0024	CbGpPWpGaD
Methamphetamine—MAOA—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000291	0.00232	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—IYD—hypothyroidism	0.00029	0.00232	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000286	0.00229	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000285	0.00228	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.000283	0.00226	CbGpPWpGaD
Methamphetamine—SLC18A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.00026	0.00208	CbGpPWpGaD
Methamphetamine—MAOA—SIDS Susceptibility Pathways—AVP—hypothyroidism	0.000251	0.00201	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A7—hypothyroidism	0.00025	0.002	CbGpPWpGaD
Methamphetamine—SLC6A4—Circadian rythm related genes—AVP—hypothyroidism	0.00025	0.002	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—ATP5O—hypothyroidism	0.000247	0.00197	CbGpPWpGaD
Methamphetamine—MAOB—Biological oxidations—POMC—hypothyroidism	0.000246	0.00197	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—IYD—hypothyroidism	0.000246	0.00196	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000241	0.00193	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000234	0.00187	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—CLTC—hypothyroidism	0.000234	0.00187	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR ligand binding—POMC—hypothyroidism	0.000233	0.00186	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—TPO—hypothyroidism	0.000232	0.00186	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000225	0.0018	CbGpPWpGaD
Methamphetamine—SLC22A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000225	0.0018	CbGpPWpGaD
Methamphetamine—SLC22A5—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000224	0.00179	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000222	0.00178	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000215	0.00172	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000215	0.00172	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—ATP5O—hypothyroidism	0.000209	0.00167	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC26A4—hypothyroidism	0.000208	0.00166	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—VAV3—hypothyroidism	0.000206	0.00165	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TRH—hypothyroidism	0.000202	0.00162	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000201	0.00161	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000201	0.00161	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—AVP—hypothyroidism	0.000198	0.00159	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—SLC5A5—hypothyroidism	0.000197	0.00158	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TPO—hypothyroidism	0.000196	0.00157	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—VAV3—hypothyroidism	0.000187	0.00149	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TRH—hypothyroidism	0.000184	0.00147	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TRH—hypothyroidism	0.000183	0.00146	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—IYD—hypothyroidism	0.000182	0.00146	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TSHB—hypothyroidism	0.00018	0.00144	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—TSHR—hypothyroidism	0.00018	0.00144	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—AVP—hypothyroidism	0.00018	0.00144	CbGpPWpGaD
Methamphetamine—SLC6A2—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000175	0.0014	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000174	0.00139	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TRH—hypothyroidism	0.000172	0.00137	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000168	0.00134	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TSHB—hypothyroidism	0.000164	0.00131	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—TSHR—hypothyroidism	0.000164	0.00131	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHB—hypothyroidism	0.000163	0.0013	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TSHR—hypothyroidism	0.000163	0.0013	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000162	0.0013	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—SH2B3—hypothyroidism	0.000161	0.00129	CbGpPWpGaD
Methamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—hypothyroidism	0.000156	0.00125	CbGpPWpGaD
Methamphetamine—SLC6A3—SLC-mediated transmembrane transport—AVP—hypothyroidism	0.000155	0.00124	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—ATP5O—hypothyroidism	0.000155	0.00124	CbGpPWpGaD
Methamphetamine—MAOA—Biological oxidations—POMC—hypothyroidism	0.000154	0.00123	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TSHR—hypothyroidism	0.000153	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—TSHB—hypothyroidism	0.000153	0.00122	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—IYD—hypothyroidism	0.00015	0.0012	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TPO—hypothyroidism	0.000146	0.00116	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000145	0.00116	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000145	0.00116	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TRH—hypothyroidism	0.000139	0.00111	CbGpPWpGaD
Methamphetamine—SLC18A2—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000132	0.00106	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—VAV3—hypothyroidism	0.000132	0.00105	CbGpPWpGaD
Methamphetamine—TAAR1—GPCR downstream signaling—POMC—hypothyroidism	0.000132	0.00105	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—SH2B3—hypothyroidism	0.00013	0.00104	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—ATP5O—hypothyroidism	0.000127	0.00102	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000127	0.00101	CbGpPWpGaD
Methamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—hypothyroidism	0.000126	0.00101	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TSHB—hypothyroidism	0.000124	0.000994	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—TSHR—hypothyroidism	0.000124	0.000994	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—SH2B3—hypothyroidism	0.000122	0.000975	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—IYD—hypothyroidism	0.000122	0.000973	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TPO—hypothyroidism	0.00012	0.000958	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling by GPCR—POMC—hypothyroidism	0.00012	0.000957	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—PRL—hypothyroidism	0.000119	0.000954	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	0.000118	0.000947	CbGpPWpGaD
Methamphetamine—SLC22A3—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000114	0.000915	CbGpPWpGaD
Methamphetamine—SLC22A5—Transmembrane transport of small molecules—AVP—hypothyroidism	0.000114	0.000912	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.000113	0.000904	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—VAV3—hypothyroidism	0.00011	0.000883	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—TSHB—hypothyroidism	0.000107	0.000859	CbGpPWpGaD
Methamphetamine—ADRA2B—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	0.000107	0.000856	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—AVP—hypothyroidism	0.000106	0.00085	CbGpPWpGaD
Methamphetamine—ADRA2B—G alpha (i) signalling events—POMC—hypothyroidism	0.000106	0.000847	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TRH—hypothyroidism	0.000104	0.00083	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—ATP5O—hypothyroidism	0.000103	0.000828	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—SLC5A5—hypothyroidism	0.0001	0.000801	CbGpPWpGaD
Methamphetamine—ADRA2C—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	9.99e-05	0.0008	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—SH2B3—hypothyroidism	9.9e-05	0.000792	CbGpPWpGaD
Methamphetamine—ADRA2C—G alpha (i) signalling events—POMC—hypothyroidism	9.89e-05	0.000791	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TPO—hypothyroidism	9.73e-05	0.000778	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TRH—hypothyroidism	9.69e-05	0.000776	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—AVP—hypothyroidism	9.65e-05	0.000772	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—AVP—hypothyroidism	9.61e-05	0.000769	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—PIK3C2A—hypothyroidism	9.57e-05	0.000766	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TRH—hypothyroidism	9.42e-05	0.000754	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TSHB—hypothyroidism	9.25e-05	0.00074	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—TSHR—hypothyroidism	9.25e-05	0.00074	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—TSHB—hypothyroidism	9.09e-05	0.000727	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—AVP—hypothyroidism	9.01e-05	0.000721	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—VAV3—hypothyroidism	8.95e-05	0.000716	CbGpPWpGaD
Methamphetamine—SLC6A2—Transmembrane transport of small molecules—AVP—hypothyroidism	8.9e-05	0.000712	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TRH—hypothyroidism	8.8e-05	0.000704	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TSHB—hypothyroidism	8.64e-05	0.000691	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—TSHR—hypothyroidism	8.64e-05	0.000691	CbGpPWpGaD
Methamphetamine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	8.42e-05	0.000674	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TSHB—hypothyroidism	8.4e-05	0.000672	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—TSHR—hypothyroidism	8.4e-05	0.000672	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—VAV3—hypothyroidism	8.36e-05	0.000669	CbGpPWpGaD
Methamphetamine—ADRA2A—Platelet activation, signaling and aggregation—IGF1—hypothyroidism	8.12e-05	0.000649	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—PIK3C2A—hypothyroidism	8.1e-05	0.000648	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—SLC5A5—hypothyroidism	8.04e-05	0.000643	CbGpPWpGaD
Methamphetamine—ADRA2A—G alpha (i) signalling events—POMC—hypothyroidism	8.03e-05	0.000643	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—IYD—hypothyroidism	7.93e-05	0.000634	CbGpPWpGaD
Methamphetamine—SLC6A3—Transmembrane transport of small molecules—AVP—hypothyroidism	7.88e-05	0.000631	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TRH—hypothyroidism	7.87e-05	0.00063	CbGpPWpGaD
Methamphetamine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	7.86e-05	0.000629	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TSHB—hypothyroidism	7.85e-05	0.000628	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—TSHR—hypothyroidism	7.85e-05	0.000628	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—AVP—hypothyroidism	7.32e-05	0.000586	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TRH—hypothyroidism	7.15e-05	0.000572	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—POMC—hypothyroidism	7.06e-05	0.000565	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TSHB—hypothyroidism	7.02e-05	0.000562	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—TSHR—hypothyroidism	7.02e-05	0.000562	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—SLC5A5—hypothyroidism	6.8e-05	0.000544	CbGpPWpGaD
Methamphetamine—TAAR1—Signaling Pathways—IGF1—hypothyroidism	6.79e-05	0.000544	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—VAV3—hypothyroidism	6.79e-05	0.000544	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—ATP5O—hypothyroidism	6.74e-05	0.000539	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—TSHB—hypothyroidism	6.74e-05	0.000539	CbGpPWpGaD
Methamphetamine—CYP2D6—Biological oxidations—POMC—hypothyroidism	6.72e-05	0.000538	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—CLTC—hypothyroidism	6.44e-05	0.000515	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR ligand binding—POMC—hypothyroidism	6.41e-05	0.000513	CbGpPWpGaD
Methamphetamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—POMC—hypothyroidism	6.39e-05	0.000511	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TSHB—hypothyroidism	6.37e-05	0.00051	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—TSHR—hypothyroidism	6.37e-05	0.00051	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TPO—hypothyroidism	6.34e-05	0.000507	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—CLTC—hypothyroidism	6.02e-05	0.000481	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—PIK3C2A—hypothyroidism	6.01e-05	0.000481	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR ligand binding—POMC—hypothyroidism	5.99e-05	0.000479	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—VAV3—hypothyroidism	5.66e-05	0.000453	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TRH—hypothyroidism	5.57e-05	0.000445	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—TSHB—hypothyroidism	5.54e-05	0.000444	CbGpPWpGaD
Methamphetamine—ADRA2B—Hemostasis—IGF1—hypothyroidism	5.51e-05	0.000441	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—AVP—hypothyroidism	5.45e-05	0.000436	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—VAV3—hypothyroidism	5.29e-05	0.000423	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TRH—hypothyroidism	5.2e-05	0.000416	CbGpPWpGaD
Methamphetamine—ADRA2C—Hemostasis—IGF1—hypothyroidism	5.15e-05	0.000412	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—VAV3—hypothyroidism	5.14e-05	0.000411	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—AVP—hypothyroidism	5.09e-05	0.000407	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—SLC5A5—hypothyroidism	5.04e-05	0.000404	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TSHB—hypothyroidism	4.96e-05	0.000397	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—TSHR—hypothyroidism	4.96e-05	0.000397	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—AVP—hypothyroidism	4.95e-05	0.000396	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—PIK3C2A—hypothyroidism	4.94e-05	0.000395	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—CLTC—hypothyroidism	4.89e-05	0.000391	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR ligand binding—POMC—hypothyroidism	4.86e-05	0.000389	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—VAV3—hypothyroidism	4.8e-05	0.000384	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TSHB—hypothyroidism	4.63e-05	0.000371	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—TSHR—hypothyroidism	4.63e-05	0.000371	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—AVP—hypothyroidism	4.62e-05	0.00037	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—TSHB—hypothyroidism	4.5e-05	0.00036	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—SH2B3—hypothyroidism	4.42e-05	0.000354	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—VAV3—hypothyroidism	4.29e-05	0.000344	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TRH—hypothyroidism	4.22e-05	0.000338	CbGpPWpGaD
Methamphetamine—MAOB—Metabolism—POMC—hypothyroidism	4.21e-05	0.000337	CbGpPWpGaD
Methamphetamine—ADRA2A—Hemostasis—IGF1—hypothyroidism	4.18e-05	0.000335	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—SLC5A5—hypothyroidism	4.15e-05	0.000332	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—AVP—hypothyroidism	4.14e-05	0.000331	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—SH2B3—hypothyroidism	4.13e-05	0.000331	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—PIK3C2A—hypothyroidism	4.01e-05	0.000321	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—VAV3—hypothyroidism	3.9e-05	0.000312	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TSHB—hypothyroidism	3.76e-05	0.000301	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—TSHR—hypothyroidism	3.76e-05	0.000301	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—AVP—hypothyroidism	3.76e-05	0.000301	CbGpPWpGaD
Methamphetamine—ADRA2B—GPCR downstream signaling—POMC—hypothyroidism	3.62e-05	0.00029	CbGpPWpGaD
Methamphetamine—SLC22A3—Metabolism—POMC—hypothyroidism	3.56e-05	0.000285	CbGpPWpGaD
Methamphetamine—ADRA2C—GPCR downstream signaling—POMC—hypothyroidism	3.38e-05	0.000271	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—SLC5A5—hypothyroidism	3.37e-05	0.00027	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—SH2B3—hypothyroidism	3.36e-05	0.000268	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling by GPCR—POMC—hypothyroidism	3.29e-05	0.000263	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—PRL—hypothyroidism	3.28e-05	0.000263	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling by GPCR—POMC—hypothyroidism	3.07e-05	0.000246	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—PRL—hypothyroidism	3.06e-05	0.000245	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—VAV3—hypothyroidism	3.04e-05	0.000243	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—TSHB—hypothyroidism	2.93e-05	0.000235	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—AVP—hypothyroidism	2.92e-05	0.000234	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—VAV3—hypothyroidism	2.84e-05	0.000227	CbGpPWpGaD
Methamphetamine—ADRA2A—GPCR downstream signaling—POMC—hypothyroidism	2.75e-05	0.00022	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—AVP—hypothyroidism	2.73e-05	0.000219	CbGpPWpGaD
Methamphetamine—MAOA—Metabolism—POMC—hypothyroidism	2.64e-05	0.000211	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—PIK3C2A—hypothyroidism	2.61e-05	0.000209	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling by GPCR—POMC—hypothyroidism	2.5e-05	0.0002	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—PRL—hypothyroidism	2.49e-05	0.000199	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—VAV3—hypothyroidism	2.3e-05	0.000184	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—AVP—hypothyroidism	2.22e-05	0.000178	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—SLC5A5—hypothyroidism	2.2e-05	0.000176	CbGpPWpGaD
Methamphetamine—ADRA2C—Metabolism—POMC—hypothyroidism	2.17e-05	0.000174	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—POMC—hypothyroidism	1.94e-05	0.000155	CbGpPWpGaD
Methamphetamine—ADRA2B—Signaling Pathways—IGF1—hypothyroidism	1.87e-05	0.00015	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—POMC—hypothyroidism	1.82e-05	0.000145	CbGpPWpGaD
Methamphetamine—ADRA2A—Metabolism—POMC—hypothyroidism	1.76e-05	0.000141	CbGpPWpGaD
Methamphetamine—ADRA2C—Signaling Pathways—IGF1—hypothyroidism	1.75e-05	0.00014	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—POMC—hypothyroidism	1.47e-05	0.000118	CbGpPWpGaD
Methamphetamine—ADRA2A—Signaling Pathways—IGF1—hypothyroidism	1.42e-05	0.000113	CbGpPWpGaD
Methamphetamine—CYP2D6—Metabolism—POMC—hypothyroidism	1.15e-05	9.19e-05	CbGpPWpGaD
